AI	Aromatase inhibitor
BRCA	Breast cancer gene
CBR	Clinical benefit rate
CDK	Cyclin-dependent kinase
CI	Confidence interval
CR	Complete response
CTCAE	Common Terminology Criteria for Adverse Event
DNA	Deoxyribonucleic acid
DoR	Duration of response
ECOG	Eastern Cooperative Oncology Group
gBRCAm	Germline BRCA1/2 mutation
gBRCAwt	Germline BRCA1/2 wild type
HER2	Human epidermal growth factor 2
HR	Hormonal receptor
HRD	Homologous repair deficiencies
HRR	Homologous recombination repair
KM Est	Kaplan–Meier estimated
mTOR	Mammalian target of rapamycin
N	Number of patients
NE	Not evaluable
NCI	National Cancer Institute
OS	Overall survival
ORR	Overall response rate
PARP	Poly (adenosine diphosphate-ribose) polymerase
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
RAD51	Radiation-sensitive gene 51
RECIST	Response Evaluation Criteria in Solid Tumors
SD	Stable disease
TEAE	Treatment-emergent adverse event
TTR	Time to response
W	Weeks
n (%)	Number of patients (percentage of patients)